Correlation Between NextCure and Candel Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NextCure and Candel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NextCure and Candel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NextCure and Candel Therapeutics, you can compare the effects of market volatilities on NextCure and Candel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NextCure with a short position of Candel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NextCure and Candel Therapeutics.

Diversification Opportunities for NextCure and Candel Therapeutics

0.44
  Correlation Coefficient

Very weak diversification

The 3 months correlation between NextCure and Candel is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding NextCure and Candel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Candel Therapeutics and NextCure is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NextCure are associated (or correlated) with Candel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Candel Therapeutics has no effect on the direction of NextCure i.e., NextCure and Candel Therapeutics go up and down completely randomly.

Pair Corralation between NextCure and Candel Therapeutics

Given the investment horizon of 90 days NextCure is expected to under-perform the Candel Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, NextCure is 1.5 times less risky than Candel Therapeutics. The stock trades about -0.11 of its potential returns per unit of risk. The Candel Therapeutics is currently generating about -0.06 of returns per unit of risk over similar time horizon. If you would invest  519.00  in Candel Therapeutics on September 4, 2024 and sell it today you would lose (62.00) from holding Candel Therapeutics or give up 11.95% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

NextCure  vs.  Candel Therapeutics

 Performance 
       Timeline  
NextCure 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Candel Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Candel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

NextCure and Candel Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NextCure and Candel Therapeutics

The main advantage of trading using opposite NextCure and Candel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NextCure position performs unexpectedly, Candel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will offset losses from the drop in Candel Therapeutics' long position.
The idea behind NextCure and Candel Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Stocks Directory
Find actively traded stocks across global markets